Know Cancer

or
forgot password

MicroRNAs as Disease Markers for Central Nervous System Tumors in Patients With Neurofibromatosis Type 1


N/A
2 Years
21 Years
Open (Enrolling)
Both
Glioma, Neurofibromatosis Type 1

Thank you

Trial Information

MicroRNAs as Disease Markers for Central Nervous System Tumors in Patients With Neurofibromatosis Type 1


Inclusion Criteria:



- Patients ages 2 years to 21 years.

- Patients with NF-1 being followed in the Neurofibromatosis Clinic.

- Patients have had MRI imaging in the 24 months prior to enrollment on the study.

- Patients may have known concurrent malignancies such as plexiform neurofibroma.

- Patients and/or parents/legal guardians must have signed an informed consent and
assent when applicable.

Exclusion Criteria:

- Patients who have had prior tumor-directed therapy (including chemotherapy and/or
radiation)

- Patients with a prior or current diagnosis of a malignant peripheral nerve sheath
tumor.

- Patients who are considered too ill to participate as determined by their treating
physician

- Patients who are pregnant or lactating

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Evaluate miRNA expression patterns in tissue of low grade gliomas

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Rishi Lulla, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Ann & Robert H Lurie Children's Hospital of Chicago

Authority:

United States: Institutional Review Board

Study ID:

2012-14927

NCT ID:

NCT01595139

Start Date:

February 2012

Completion Date:

Related Keywords:

  • Glioma
  • Neurofibromatosis Type 1
  • Glioma
  • Nervous System Neoplasms
  • Neurofibromatoses
  • Neurofibromatosis 1
  • Osteitis Fibrosa Cystica
  • Central Nervous System Neoplasms

Name

Location

Children's Memorial HospitalChicago, Illinois  60614